This study looks at the use of two medicines, avutometinib and defactinib, to see if they work well together for treating thyroid cancer. The focus is on patients with specific types of thyroid cancer that do not respond to standard treatments. Researchers want to know if this combination is safe and leads to positive results for patients.
The trial's ID number is NCT06007924. It is in Phase 2, which means researchers are examining how well the treatment works and its safety. This study is regulated by the FDA and aims to include about 30 participants.
Who can join
The trial is open to adults aged 18 and older, including both men and women. Patients must have certain types of thyroid cancer that have specific genetic features. They should have measurable disease and must not have had recent treatments that could interfere with the study. The trial team will check to see if interested individuals meet all eligibility requirements.
Condition
Thyroid Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups based on their type of thyroid cancer. Everyone in both groups will receive the same treatment: 3.2 mg of avutometinib twice a week and 200 mg of defactinib twice daily, following a specific schedule of 3 weeks on treatment and 1 week off. This is a non-randomized study, meaning participants are assigned to a group based on their condition rather than by chance.
Where
This trial is enrolling at 7 locations. Recruiting sites are listed first.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York
Recruiting
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)
Commack, New York
Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Rockville Centre, New York
Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
A surgeon who treats mouth cancer and voice box cancer at Rajiv Gandhi Cancer Institute & Research Centre. Treats mouth cancer, voice box cancer, throat cancer and thyroid cancer.
Professor of Medicine at the University of Kentucky College of Medicine and Director of the Thyroid Oncology Program. Treats thyroid cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.
Professor of Medicine and Chief of the Division of Medical Oncology at the University of Kentucky Markey Cancer Center. Treats thyroid cancer and parathyroid cancer.